Evidence map›Paper›PMID 36188636›Full record

ArticleDrugs in context2022

Cannabidiol as a personalized treatment for anxiety: clinical cases in Mexico.

Flor Cristina Ortiz Rios, Itzel Guadalupe Dávila Ruiz, Elisa Sacal Dumani

Abstract readCase Reports
In one paragraph

Article in Drugs in context, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Flor Cristina Ortiz RiosICAN Instituto del Cannabis, Mexico City, Mexico.ORCID https://orcid.org/0000-0002-2816-9823
Itzel Guadalupe Dávila RuizICAN Instituto del Cannabis, Mexico City, Mexico.
Elisa Sacal DumaniPrivate practice, CEO & Cofounder of the Family Sleep Institute - Spanish (FSI), Cofounder of the Asociación Mexicana de Medicina de Estilo de Vida, Mexico City, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anxiety-related disorders are one of the most common mental health issues worldwide. Mexico has reported an increase in the prevalence of these ailments secondary to the confinement derived from the COVID-19 pandemic. Given the limitations of commonly used treatments for these disorders, a need arises to develop new pharmacological treatments for these patients. This paper has the primary objective of evaluating the efficacy and safety of cannabidiol isolate in drug compounding used as a personalized treatment in patients with anxiety disorders through the presentation of four clinical cases.

Indexed as

anxietycannabidiolCBDdelta-9-tetrahydrocannabinolendocannabinoid systeminsomniamedical cannabis

Identifiers

PMID36188636
PMCPMC9491383

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.